A venture capital fund set up in 2018 to invest in early-stage companies with novel antibiotic programmes is to dispense nearly $12 million to companies in France and the US. They are Mutabilis SA, which is developing antibacterials against Gram-negative infections and IBT Vaccines, a subsidiary of Integrated Biotherapeutics Inc, which has an experimental vaccine for Staphylococcus aureus in development.
Mutabilis of Romainville, France will receive €7 million ($7.83 million) and IBT of Rockville, Maryland, US will receive $3.9 million.